CDK4 and Hyperglycemia: Regarding hyperglycemia, compared with CDK4/6 inhibitors, three of four PI3K inhibitors were more likely to induce hyperglycemia of all grades, including alpelisib (OR, 11.0; 95% CrI, 2.3–50.0), burparlisib (OR, 10.0; 95% CrI, 2.9–48.0), and taselisib (OR, 6.5; 95% CrI, 1.6–34.0), whereas pictilisib, capivasertib, and everolimus showed the same trend without salient discrepancy (Supplementary Figure 14).